U.S. investors, Big Pharma race to find new medicines in China
U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
BioSpace4d
Bain Bets Big on Japanese Market With $3.3B Tanabe Buy
The carve-out acquisition will allow Bain to capitalize on the “promising signs for growth” in the Japanese life sciences ...
ジャパンタイムズ5d
Bain to acquire Mitsubishi Tanabe Pharma in $3.3 billion deal
Tanabe Pharma focuses on therapeutic areas such as immunology and inflammation, vaccines, diabetes, and central nervous ...
C&EN4d
Mitsubishi Chemical to sell drug business to Bain
Chemical companies in the US and Europe began exiting the pharmaceutical industry in the mid-1990s, when the British firm ICI ...
The Pharma Letter2d
Abcuro closes $200 million Series C financing
Massachusetts, USA-based cell therapy specialist Abcuro today announced the closing of a $200 million Series C financing.
Pharm Exec2d
Abcuro Secures $200 Million in Series C Funding to Advance Ulviprubart for Inclusion Body Myositis
Funding was led by New Enterprise Associates, with participation from Foresite Capital and multiple other investors.
Le Lézard2d
Abcuro Announces $200 Million Series C Financing to Advance Its First-In-Class Medicine in Development for Inclusion Body Myositis
Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced the ...
Hosted on MSN6d
Bain Capital buys Mitsubishi Tanabe Pharma for $3.3bn
Bain said its decision to buy Mitsubishi Tanabe is due to the “strong growth potential” of Japan’s healthcare industry.
Carlyle adds Roop Automotives and Highway Industries to its auto parts platform
Through this platform, Carlyle will help Roop and Highway leverage operating synergies, create capabilities and capacities ...